NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

Summary

Prospective, non-randomized, open-label, single-arm phase II trial to investigate the feasibility and efficacy of combining chemotherapy with tiragolumab and atezolizumab as neoadjuvant and adjuvant treatment for surgical NSCLC patients.

Timeline

Start

2023-05-26

Primary completion

2026-12-01

Completion

2027-06-01

Publications

• Roesch RM, Schnorbach J, Klotz LV, Griffo R, Thomas M, Stenzinger A, Christopoulos P, Allgaeuer M, Schneider M, Schuler M, Wiesweg M, Schramm A, Bolukbas S, Doerr F, Hegedus B, Cvetkovic J, Kirchner M, Eichhorn ME, Winter H, Bozorgmehr F, Eichhorn F. NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy - dissection of IO- efficacy in NSCLC by longitudinal tracKing - protocol of a non-randomised, open-label, single-arm, phase II study. BMJ Open. 2025 Mar 27;15(3):e096617. doi: 10.1136/bmjopen-2024-096617.

Drugs

Indications